SecBot SecBot
PRESS-RELEASE ·Filed May 11, 2026

FATE

Fate Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The FT819 data showing efficacy without conditioning chemotherapy is a significant differentiator in the competitive CAR T landscape. Monitor for additional FT819 dose level 2 data and potential regulatory alignment for registrational path. FT839 and FT836 preclinical data support pipeline optionality but are early stage.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.18
T+0 close · May 11, 2026 · via day close
Latest settled
+19.27%
T+60 · $2.60
Vs SPY
+14.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $2.18entry
  2. T+1 · 6mo ago +3.21%α +3.35% · $2.25
  3. T+5 · 6mo ago −20.64%α −20.56% · $1.73
  4. T+20 · 5mo ago −12.84%α −12.54% · $1.90
  5. T+60 · 3mo ago +19.27%α +14.87% · $2.60
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fate Therapeutics presented clinical and preclinical data at ASGCT 2026 for its off-the-shelf iPSC-derived CAR T-cell programs. FT819 showed 3/3 SLE patients achieving SRI-4 and 2/3 achieving LLDAS with durable B-cell remodeling up to 12 months without conditioning chemotherapy. Preclinical data for FT839 and FT836 demonstrated broad depletion of pathogenic cells and synergy with standard-of-care therapies. The data supports the company's platform approach to eliminate conditioning chemotherapy, potentially expanding patient access.

Key Facts

  • FT819: 3/3 SLE patients achieved SRI-4, 2/3 achieved LLDAS at dose level 1 without conditioning chemotherapy.
  • FT819: 79% average depletion of major B cell clones lasting up to 12 months post single dose.
  • FT839 preclinical: >99% depletion of B cells, plasmablasts, plasma cells; >90% depletion of activated T cells in RA and SLE samples.
  • FT839: Persistence enhanced ~60x vs. unmodified CAR T via Sword and Shield technology.
  • FT836 preclinical: Up to 100% tumor control in xenograft models as monotherapy or with mAbs; cytolytic activity enhanced ~5x with chemo/radiotherapy.
  • FT836: Phase 1 clinical trials ongoing in solid tumors (NCT07216105) and multiple myeloma (NCT07221032).
  • FT819 dose level 2 (900M cells) enrollment initiated.

Financial Impact

No financial figures disclosed in press release. Positive clinical data may support future regulatory filings and partnership opportunities.

clinical trial enrollmentregulatory pathpotential revenue

Risk Factors

  • Clinical data is early-stage (Phase 1, small sample size) and may not replicate in larger trials.
  • FT819 dose level 2 data not yet available; higher doses may have safety or efficacy issues.
  • FT839 and FT836 are preclinical; clinical validation is years away.
  • Company has no approved products and relies on future financing or partnerships.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
61% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3291886

Track record

21 reports on FATE

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  2. Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  3. Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
  4. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  6. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  7. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  8. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
  9. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
  10. Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026